Literature DB >> 8182002

Susceptibility of Moraxella catarrhalis isolates to beta-lactam antibiotics in relation to beta-lactamase pattern.

C P Fung1, S F Yeo, D M Livermore.   

Abstract

Moraxella catarrhalis isolates (n = 413) were collected from 20 clinical laboratories in England and Scotland in 1991 and were examined for beta-lactamase production by isoelectric focusing. beta-Lactamases were found in 375 isolates of which, 349 (93.1%) had BRO-1 enzyme and 26 (6.9%) had BRO-2. Minor variation in electrofocusing pattern occurred within both enzyme types. Ampicillin MICs for BRO-1 producers were 25-fold higher than for non-producers, but those for BRO-2 producers were raised only four-fold. MICs of cefaclor, cefixime, loracarbef, co-amoxiclav and cefetamet generally were two- to four-fold higher for BRO-1 producers than for BRO-2 producers and enzyme non-producers. Similarly, the inhibition zones of discs containing cefaclor, cefixime, loracarbef or co-amoxiclav were smaller for BRO-1 producers than for non-producers. Amongst the compounds tested, cefetamet seemed the least affected by beta-lactamase production in both MIC and disc tests. Overall, these results indicate that BRO-1 enzyme predominates amongst M. catarrhalis isolates from the UK, as in other countries, and suggest that BRO-1 production gives slight protection against many of the newer oral beta-lactams as well as causing ampicillin resistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182002     DOI: 10.1093/jac/33.2.215

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Authors:  S S Richter; P L Winokur; A B Brueggemann; H K Huynh; P R Rhomberg; E M Wingert; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.

Authors:  Franz-Josef Schmitz; Andreas Beeck; Mirella Perdikouli; Mechthild Boos; Susanne Mayer; Sybille Scheuring; Karl Köhrer; Jan Verhoef; Ad C Fluit
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

3.  Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004).

Authors:  Lalitagauri M Deshpande; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Interaction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm system.

Authors:  R K Budhani; J K Struthers
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 5.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

6.  Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin?

Authors:  H J Bootsma; P C Aerts; G Posthuma; T Harmsen; J Verhoef; H van Dijk; F R Mooi
Journal:  J Bacteriol       Date:  1999-08       Impact factor: 3.490

Review 7.  Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs.

Authors:  David A Sanchez; Luis R Martinez
Journal:  Crit Rev Microbiol       Date:  2018-12-06       Impact factor: 7.624

Review 8.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis.

Authors:  H J Bootsma; H van Dijk; J Verhoef; A Fleer; F R Mooi
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.

Authors:  Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-05-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.